

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
4821-528-999APPLICATION NO.
101693980APPLICANT
T. Jerussi

FILING DATE

10/28/03

GROUP

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PS	AA	6,127,363	10/2000	Doherty et al.	514	220	
PS	AB	6,174,925	01/2001	Bailey et al.	514	646	
PS	AC	6,046,242	11/1998	Emmelmann	514	650	
PS	AD	5,795,880	08/1998	Svec et al.	514	109	
PS	AE	5,780,051	07/1998	Eswara et al.	424	444	
PS	AF	5,733,566	03/1998	Lewis	424	426	
PS	AG	5,719,283	02/1998	Bell et al.	514	262	
PS	AH	5,674,553	10/1997	Shinoda et al.	427	68	
PS	AI	5,639,476	06/1997	Oshlack et al.	424	468	
PS	AJ	5,591,767	01/1997	Mohr et al.	514	413	
PS	AK	5,552,429	09/1996	Wong et al.	514	415	
PS	AL	5,459,164	10/1995	Vargas	514	646	
PS	AM	5,436,272	07/1995	Scheinbaum	514	646	
PS	AN	5,354,556	10/1994	Sparks et al.	424	419	
PS	AO	5,250,534	10/1993	Bell et al.	514	258	
PS	AP	5,120,548	06/1992	McClelland et al.	424	473	
PS	AQ	5,104,899	04/1992	Young et al.	514	646	
PS	AR	5,073,543	12/1991	Marshall et al.	514	21	
PS	AS	5,068,440	11/1991	Jeffery et al.	564	442	
PS	AT	5,059,595	10/1991	Le Grazie	424	468	
PS	AU	4,988,814	01/1991	Abou-Gharbia et al.	544	295	
PS	AV	4,939,175	07/1990	Ukai et al.	514	646	
PS	AW	4,929,629	05/1990	Jeffery	514	646	
PS	AX	4,871,774	10/1989	Rees	514	646	
PS	AY	4,816,488	03/1989	Rees	514	646	
PS	AZ	4,814,352	03/1989	Jeffery et al.	514	646	
PS	BA	4,806,570	02/1989	Jeffery et al.	514	646	
PS	BB	4,746,680	05/1988	Jeffery et al.	514	646	
PS	BC	4,552,828	11/1985	Toya et al.	430	217	
PS	BD	4,522,828	06/1985	Jeffery et al.	514	646	
PS	BE	4,008,719	02/1977	Theeuwes et al.	128	260	
PS	BF	3,960,891	06/1976	Malen et al.	260	327	

Phyllis Spivack

12/19/05

PS	BG	3,916,899	11/1975	Theeuwes et al.	128	127		
PS	BH	3,845,770	11/1974	Theeuwes et al.	128	260		
PS	BI	3,598,123	08/1971	Zaffaroni	128	268		
PS	BJ	3,536,809	10/1970	Applezweig	424	28		
PS	BK	3,471,515	10/1969	Troxler et al.	260	326.15		
PS	BL	3,155,670	11/1964	Janssen et al.	260	294		
PS	BM	3,155,669	11/1964	Janssen et al.	260	294		
FOREIGN PATENT DOCUMENTS								
PS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
PS	BN	WO 00/56322	09/2000	PCT	1			
PS	BO	WO 00/56321	09/2000	PCT	1			
PS	BP	WO 00/56318	09/2000	PCT	1			
PS	BQ	WO 00/56315	09/2000	PCT	1			
PS	BR	WO 00/56314	09/2000	PCT	1			
PS	BS	WO 00/56309	09/2000	PCT	1			
PS	BT	WO 00/56306	09/2000	PCT	1			
PS	BU	WO 00/56151	09/2000	PCT	1			
PS	BV	WO 00/56150	09/2000	PCT	1			
PS	BW	WO 00/56149	09/2000	PCT	1			
PS	BX	WO 00/56148	09/2000	PCT	1			
PS	BY	WO 00/54765	09/2000	PCT	1			
PS	BZ	WO 00/32182	11/1998	PCT	1			
PS	CA	WO 99/33450	07/1999	PCT	1			
PS	CB	WO 98/13034	04/1998	PCT	1			
PS	CC	WO 98/13033	04/1998	PCT	1			
PS	CD	WO 98/11884	03/1998	PCT	1			
PS	CE	WO 98/06722	02/1998	PCT	1			
PS	CF	EP 0 781 561 A1	07/1997	EPO	1			
PS	CG	WO 97/20810	06/1997	PCT	1			
PS	CH	WO 97/03675	02/1997	PCT	1			
PS	CI	WO 95/21615	08/1995	PCT	1			
PS	CJ	WO 95/20949	08/1995	PCT	1			
PS	CK	WO 94/28902	12/1994	PCT	1			
PS	CL	WO 94/00114	01/1994	PCT	1			
PS	CM	WO 94/00047	01/1994	PCT	1			
PS	CN	WO 90/06110	06/1990	PCT	1			
PS	CO	WO 88/06444	09/1988	PCT	1			
PS	CP	DE 32 12 682 A1	10/1982	Germany				
PS	CQ	GB 2098602 A	11/1982	United Kingdom				

Phyllis Spivack 12/14/05

PS	CR	EP 0 035 597	9/1981	Europe			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
PS	CS	Baldessarini et al., <i>Life Sciences</i> 39: 1765-1777, (1986).					
PS	CT	Buckett et al., "BTS 54 524-An Approach to Rapidly Acting Antidepressant," <i>New Concepts in Depression</i> 2: 167-172 (1988).					
PS	CU	Bucket et al., "The Pharmacology of Sibutramine Hydrochloride (BTS 54 524), A New Antidepressant which induces Rapid Noradrenergic Down-Regulation", <i>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</i> 12: 575-584 (1988).					
PS	CV	Buckett et al., "Sibutramine Hydrochloride," <i>Drugs of the Future</i> 13(8): 736-738 (1988).					
PS	CW	Butler, D., <i>Facile Cycloalkylation of Arylacetonitriles in Dimethyl Sulfoxide</i> , <i>J. Org. Chem.</i> , 36:1308-1309 (1971).					
PS	CX	Canonne, P., et al., <i>Effet du Benzene Dans la Reaction de Grignard sur les Nitriles</i> , <i>Tetrahedron Lett.</i> , 21:155-58 (1980).					
PS	CY	Carstensen, J., <i>Drug Stability: Principles & Practice</i> , 2d. Ed., pp. 379-80, Marcel Dekker, NY, NY, (1995).					
PS	CZ	Castello, R.A., et al., <i>Discoloration of Tablets Containing Amines and Lactose</i> , <i>Pharm. Sci.</i> 51(2):106-108 (1962).					
PS	DA	Cheetham, S.C., et al., [³ H]Paroxetine Binding in Rat Frontal Cortex Strongly Correlates with [³ H]5-HT Uptake: Effect of Administration of Various Antidepressant Treatments, <i>Neuropharmacology</i> (1993), 32(8), 737-743.					
PS	DB	Cliffe et al., (S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: A Selective Antagonist at Presynaptic and Postsynaptic 5-HT _{1A} Receptors, <i>Med. Chem.</i> , 36:1509-1510 (1993).					
PS	DC	<i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fourth Ed., American Psychiatric Association, (1997).					
PS	DD	<i>Diagnostic and Statistical Manual of Mental Disorders</i> , 3rd Ed., American Psychiatric Association (1981).					
PS	DE	Dreshfield et al., <i>Enhancement of Fluoxetine-Dependent Increase of Extracellular Serotonin (5-HT) Levels by (-)-Pindolol, an Antagonist at 5-HT_{1A} Receptors</i> , <i>Neurochem. Res.</i> , 21(5):557-562 (1996).					
PS	DF	Eliel, E.L., <i>Stereochemistry of Carbon Compounds</i> (McGraw-Hill, NY, 1962).					
PS	DG	Evans et al., "Prevalence of Alzheimer's Disease in a Community Population of Older Persons," <i>J.A.M.A.</i> 262: 2551-2556 (1989).					
PS	DH	Fuentes, J. et al., "Comparison of the apparent anti-depressant activity of (-) and (+) tranylpromine in an animal model", <i>Chemical Abstracts</i> , 85: 7, page 31, No. 40768t (1976).					
PS	DI	Goodman & Gilman, <i>The Pharmacological Basis of Therapeutics</i> , 362-373, 404 (9 th ed. McGraw-Hill, 1996).					
PS	DJ	Gray et al., <i>The Involvement of the Opioidergic System in the Antinociceptive Mechanism of Action of Antidepressant Compounds</i> , <i>BR.J. Pharmacol.</i> , Vol. 124, No. 4, (1998) pp 669-674.					
PS	DK	<i>Handbook of Pharmaceutical Excipients</i> , 2 nd ed., Wade and Willer eds., pp. 257-259 (1994).					
PS	DL	Heal et al., <i>A Comparison of the Effects on Central 5-HT Function of Sibutramine Hydrochloride and Other Weight-Modifying Agents</i> , <i>BR.J. Pharmacol.</i> (1998), 125(2), 301-308.					
PS	DM	Hillver et al., (S)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralix: A Putative 5-HT _{1A} Receptor Antagonist, <i>J. Med. Chem.</i> , 33:1541-44 (1990).					
PS	DN	<i>J. Med. Chem.</i> , Vol. 36, No. 17, 2540 (1993).					
PS	DO	<i>Introduction to Pharmaceutical Dosage Forms</i> , 4th ed., Lea & Febiger, Philadelphia (1985).					
PS	DP	Jacques et al., "Enantiomers, Racemates and Resolutions," (Wiley-Interscience, NY, 1981).					
PS	DQ	Jamali et al., <i>Journal of Pharmaceutical Sciences</i> , 78: 9: 695-715 (1989).					
PS	DR	Jeffery et al., <i>Synthesis of Sibutramine, A Novel Cyclobutylalkylamine Useful in the Treatment of Obesity, and its Major Human Metabolites</i> , <i>J. Chem. Soc. Perkin. Trans. 1</i> , 2583-2589 (1996).					

Phyllis Spivack

12/14/05

PS	DS	King et al., "Clinical Pharmacology of Sibutramine Hydrochloride (BTS 54524) A New Antidepressant, in Healthy Volunteers," <i>Clinical Pharmac.</i> 26: 607-611 (1989).
PS	DT	Kula et al., "Effects of N-Substituted Phenyltetrahydropyridines on Cerebral High-Affinity Synaptosomal Uptake of Dopamine and Other Monoamines in Several Mammalian Species," <i>Life Sciences</i> 34(26): 2567-2575, (1984).
PS	DU	Luscombe et al., <i>The Contribution of Metabolites to the Rapid and Potent Down-Regulation of Rat Cortical β-Adrenoceptors by the Putative Antidepressant Sibutramine Hydrochloride</i> , Neuropharmacology, Vol. 28, No. 2, (1989) pp 129-134.
PS	DV	The Merck Manual of Diagnosis and Therapy, 7th Ed., Merck & Co., Inc., Whitehouse Station, NJ, (1999).
PS	DW	Middlemiss et al., <i>Centrally Active 5-HT Receptor Agonists and Antagonists</i> , Neurosci. and Biobehv. Rev., 16:75-82 (1992).
PS	DX	Moreau et al., <i>Behavioral Profile of the 5-HT_{1A} Receptor Antagonist (S)-UH-301 in Rodents and Monkeys</i> , Brain Res. Bull., 29:901-04 (1992).
PS	DY	Nakada et al., <i>An Enantioconvergent Route to (-)-Kainic Acid</i> , Tetrahedron Lett., 38:857-860 (1997).
PS	DZ	Physician's Desk Reference® 473-475 (53rd ed., 1999).
PS	EA	Physician's Desk Reference® 475-476 (53rd ed., 1999).
PS	EB	Physician's Desk Reference® 764-766 (53rd ed., 1999).
PS	EC	Physician's Desk Reference® 823-825 (53rd ed., 1999).
PS	ED	Physician's Desk Reference® 978-979 (53rd ed., 1999).
PS	EE	Physician's Desk Reference® 1054-1056 (53rd ed., 1999).
PS	EF	Physician's Desk Reference® 1332-1334 (53rd ed., 1999).
PS	EG	Physician's Desk Reference® 1369-1370 (53rd ed., 1999).
PS	EH	Physician's Desk Reference® 1432-1436 (53rd ed., 1999).
PS	EI	Physician's Desk Reference® 1494-1498 (53rd ed., 1999).
PS	EJ	Physician's Desk Reference® 1641-1645 (53rd ed., 1999).
PS	EK	Physician's Desk Reference® 2004-2009 (53rd ed., 1999).
PS	EL	Physician's Desk Reference® 2075-2078 (53rd ed., 1999).
PS	EM	Physician's Desk Reference® 2190-2192 (53rd ed., 1999).
PS	EN	Physician's Desk Reference® 2367-2368 (53rd ed., 1999).
PS	EO	Physician's Desk Reference® 2396-2399 (53rd ed., 1999).
PS	EP	Physician's Desk Reference® 2490-2493 (53rd ed., 1999).
PS	EQ	Physician's Desk Reference® 2516-2521 (53rd ed., 1999).
PS	ER	Physician's Desk Reference® 2688-2691 (53rd ed., 1999).
PS	ES	Physician's Desk Reference® 2701-2704 (53rd ed., 1999).
PS	ET	Physician's Desk Reference® 2720-2726 (53rd ed., 1999).
PS	EU	Physician's Desk Reference® 2735-2736 (53rd ed., 1999).
PS	EV	Physician's Desk Reference® 2886-2888 (53rd ed., 1999).
PS	EW	Physician's Desk Reference® 2908-2910 (53rd ed., 1999).
PS	EX	Physician's Desk Reference® 3092-3094 (53rd ed., 1999).
PS	EY	Physician's Desk Reference® 3101-3104 (53rd ed., 1999).

Phyllis Spinack

12/9/05

PS	EZ	Physician's Desk Reference® 3224-3225 (53 rd ed., 1999),
PS	FA	Physician's Desk Reference® 3267-3272 (53 rd ed., 1999),
PS	FB	Physician's Desk Reference® 3307-3309 (53 rd ed., 1999),
PS	FC	Physician's Desk Reference® 3383-3384 (53 rd ed., 1999),
PS	FD	Physician's Desk Reference® 2520 (52 nd ed., 1998),
PS	FE	Physician's Desk Reference® 2958 (52 nd ed., 1998),
PS	FF	Remingtons: The Practice of The Science and Pharmacy, 19 th ed., Gennaro, ed., p. 1625 (1995),
PS	FG	Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton PA (1990).
PS	FH	Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing, Easton PA (1980).
PS	FI	Stock, M.J., Sibutramine: A Review of the Pharmacology of a Novel Anti-Obesity Agent, Int'l J. Obesity, 21(Supp. 1):S25-S29 (1997),
PS	FJ	U.S. Pharmacopia (USP) SP (XXI)/NF (XVI) (1985).
PS	FK	Wilen et al., Tetrahedron, 2725-36 33(21) (1977).
PS	FL	Wilen, S.H., Tables of Resolving Agents and Optical Resolutions 268 (E.L. Eliel ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972).
EXAMINER		Phyllis Spinack
		DATE CONSIDERED 12/19/05
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		